Company Description
Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care.
The company’s product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy.
The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults.
The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014.
Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 1983 |
| IPO Date | Aug 26, 1987 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 126 |
| CEO | Craig Collard |
Contact Details
Address: 4242 Campus Point Court, Suite 200 San Diego, California 92121 United States | |
| Phone | 858 251 4400 |
| Website | herontx.com |
Stock Details
| Ticker Symbol | HRTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000818033 |
| CUSIP Number | 427746102 |
| ISIN Number | US4277461020 |
| Employer ID | 94-2875566 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Craig Alexander Collard | Chief Executive Officer and Director |
| Ira Duarte | Executive Vice President and Chief Financial Officer |
| Dr. William P. Forbes Pharm. D., Pharm.D. | Executive Vice President and Chief Development Officer |
| Ryan Craig | Vice President of Marketing |
| Sean T. Ristine | Senior Vice President of Human Resources |
| Robert Sullivan | Senior Vice President of Oncology Care Franchise and Commercial Operations |
| Brett Fleshman | Chief Business Officer |
| Jeff Cohn | Executive Director, Assistant General Counsel and Assistant Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 24, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Aug 6, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Aug 6, 2024 | 10-Q | Quarterly Report |
| Aug 6, 2024 | 8-K | Current Report |
| Jul 2, 2024 | 8-K | Current Report |
| Jun 18, 2024 | 8-K | Current Report |
| May 31, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| May 29, 2024 | 8-K | Current Report |
| May 7, 2024 | 10-Q | Quarterly Report |
| May 7, 2024 | 8-K | Current Report |